Clinical trial
Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme…
NCT00102648 · M.D. Anderson Cancer Center, Other · Active, not recruiting
Key facts
| NCT number | NCT00102648 |
|---|---|
| Title | Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide |
| Official title | Phase I/Ib Study of Sarasar and Temodar in Patients with Recurrent or Temodar-Refractory Glioblastoma Multiforme |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Active, not recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Malignant Supratentorial Neoplasm, Recurrent Glioblastoma, Recurrent Gliosarcoma |
| Intervention type | Drug |
| Interventions | Lonafarnib, Temozolomide |
| Enrollment | 34 |
| Start date | Dec 21, 2004 |
| Primary completion | Mar 1, 2025 |
| Completion | Dec 1, 2025 |
| First posted | Feb 1, 2005 |
| Last update posted | Oct 17, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: